Related Experiment Video
Updated: May 28, 2026
07:36
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Pro-inflammatory and vasoconstricting prostanoid PGF2α causes no headache in man
Maria Antonova1, Troels Wienecke, Jes Olesen
1University of Copenhagen, Denmark.
Cephalalgia : an International Journal of Headache
|October 21, 2011
Summary
Prostaglandin F2α (PGF2α) did not cause headaches in healthy volunteers, unlike other prostaglandins. This suggests that the headache-inducing effects of prostaglandins are linked to their vasodilating properties.
Area of Science:
- Neuroscience
- Pharmacology
- Physiology
Background:
- Previous research linked vasodilating prostaglandins (e.g., PGE2, PGI2, PGD2) to experimental headache induction.
- The role of inflammation and vasodilation in headache generation requires further elucidation.
Purpose of the Study:
- To investigate if prostaglandin F2α (PGF2α), a pro-inflammatory and vasoconstricting prostanoid, can induce headache in humans.
- To explore the relationship between prostaglandin properties and headache generation.
Main Methods:
- A randomized, two-way crossover study involving 12 healthy volunteers.
- Administration of PGF2α (3.5 µg/kg/min for 20 min) or placebo.
- Assessment of headache intensity, middle cerebral artery blood flow velocity (V(MCA)), and superficial temporal artery (STA) and radial artery (RA) diameters.
Main Results:
- No significant difference in headache incidence or intensity between PGF2α and placebo groups.
- No significant changes in V(MCA), STA diameter, or RA diameter were observed.
- PGF2α did not provoke immediate or delayed headache.
Conclusions:
- Prostaglandin F2α (PGF2α) does not induce experimental headache in healthy volunteers.
- The vasodilating properties of prostaglandins appear crucial for inducing experimental headache.
- Findings suggest a specific mechanism for prostaglandin-induced headaches, distinct from PGF2α's effects.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Inflammation: Introduction
Inflammation is a fundamental, protective biological response of vascularized tissues to cellular injury, infection, or harmful stimuli. Its primary function is to eliminate the initial cause of injury, clear necrotic cells and damaged tissue, and initiate the necessary repair processes.Cardinal SignsAcute inflammation presents with classic signs. Redness results from vasodilation and increased blood flow. Heat is due to increased metabolism and circulation. Swelling results from the...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...